Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Invitae borrows against the future
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
Corporate investing plays an ever bigger role in medtech
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
